Jessen, F, Arbizu, J, Boada, M, Balasa, M, Bennys, K, Boban, M, Bürger, K, Chincarini, A, Cagnin, A, De Deyn, PP, Düzel, E, Engelborghs, S, Ewers, M, Exalto, LG, van der Flier, WM, Fortea, J, Frederiksen, KS, Frisoni, GB, Frölich, L, Garza-Martinez, AJ, Grimmer, T, Hanseeuw, B, Hort, J, Ivanoiu, A, Kehoe, PG, Kennelly, SP, Kern, S, Klöppel, S, Krajcovicová, L, Kramberger, MG, McGuinness, B, Mecocci, P, Oberstein, TJ, Ousset, PJ, Paquet, C, Perneczky, R, Piazza, F, Plantone, D, Rainero, I, Sacco, G, Salm, E, Santana, I, Scarmeas, N, Schneider, A, Schott, JM, Solje, E, Stefanova, E, Stögmann, E, Strauss, M, Sutovsky, S, Waldemar, G, Winblad, B. Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease. JPAD-Journal of Prevention of Alzheimers Disease. 2025; 12(8)DOI:10.1016/j.tjpad.2025.100259. PMID:40640062. IF:7.800(Q1/1D).

Rafii, MS, Schlachetzki, Z, Barroeta, I, Head, E, Fortea, J, Ances, BM. Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology. LANCET NEUROLOGY. 2025; 24(9)DOI:10.1016/S1474-4422(25)00237-6. PMID:40818475. IF:45.500(Q1/1D).

Hok-A-Hin, YS, Vermunt, L, Peeters, CFW, van der Ende, EL, de Boer, SCM, Meeter, LH, de Houwer, J, Seelaar, H, van Swieten, JC, Hu, WT, Lleó, A, Alcolea, D, Engelborghs, S, Sieben, A, Chen-Plotkin, A, Irwin, DJ, van der Flier, WM, Pijnenburg, YAL, Teunissen, CE, del Campo, M. Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia. Molecular Neurodegeneration. 2025; 20(1)DOI:10.1186/s13024-025-00882-5. PMID:40866991. IF:17.500(Q1/1D).

Giner-Soriano, M, Morros, R, Monfà, R, Ouchi, D, Fernández-García, S, Vedia, C, Monné, SB, Martínez, EMC, Fanlo, SC, Morollón, N, Nieto, RB, Delgado-Espinoza, CE, García-Sangenís, A. Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: study protocol for a pragmatic clinical trial (PREMI study). Trials. 2025; 26(1)DOI:10.1186/s13063-025-08961-0. PMID:40859286. IF:2.000(Q3/7D).